|
Play Video: The Importance of Insider Buying
|
|
|
The table below summarizes the most recent Sensei Biotherapeutics insider buying information, with links below the price to see the
CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many
possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more
information about why Sensei Biotherapeutics insider buys are important for investors to follow.
Date | Insider | Price | Amount |
9-11-2023 Insider Buy |
John Celebi President and CEO |
$0.85
CAGR »
|
$425.00 500 shares |
2-23-2023 Insider Buy |
Investment Group LTD. Apeiron >10% Owner |
$1.61
CAGR »
|
$3,539.03 2,200 shares |
3-2-2022 Insider Buy |
Biopharma Inc Cambrian >10% Owner |
$3.20
CAGR »
|
$3,849.60 1,203 shares |
2-24-2022 Insider Buy |
James Peyer Director and >10% Owner |
$3.65
CAGR »
|
$63,950.00 17,500 shares |
2-18-2022 Insider Buy |
Biopharma Inc Cambrian >10% Owner |
$4.02
CAGR »
|
$80,187.33 19,949 shares |
2-18-2022 Insider Buy |
James Peyer Director and >10% Owner |
$4.02
CAGR »
|
$80,187.33 19,949 shares |
2-16-2022 Insider Buy |
James Peyer Director and >10% Owner |
$4.19
CAGR »
|
$52,641.75 12,551 shares |
2-16-2022 Insider Buy |
Biopharma Inc Cambrian >10% Owner |
$4.19
CAGR »
|
$52,641.75 12,551 shares |
2-8-2022 Insider Buy |
James Peyer Director and >10% Owner |
$4.53
CAGR »
|
$135,800.00 30,000 shares |
2-8-2022 Insider Buy |
Biopharma Inc Cambrian >10% Owner |
$4.53
CAGR »
|
$135,800.00 30,000 shares |
1-28-2022 Insider Buy |
James Peyer Director and >10% Owner |
$4.26
CAGR »
|
$63,849.00 15,000 shares |
1-28-2022 Insider Buy |
Biopharma Inc Cambrian >10% Owner |
$4.26
CAGR »
|
$63,849.00 15,000 shares |
1-26-2022 Insider Buy |
Biopharma Inc Cambrian >10% Owner |
$4.72
CAGR »
|
$235,824.00 50,000 shares |
1-26-2022 Insider Buy |
James Peyer Director and >10% Owner |
$4.72
CAGR »
|
$235,824.00 50,000 shares |
1-24-2022 Insider Buy |
Biopharma Inc Cambrian >10% Owner |
$4.82
CAGR »
|
$228,528.65 47,410 shares |
1-24-2022 Insider Buy |
James Peyer Director and >10% Owner |
$4.82
CAGR »
|
$228,528.65 47,410 shares |
1-20-2022 Insider Buy |
Biopharma Inc Cambrian >10% Owner |
$5.10
CAGR »
|
$154,312.68 30,244 shares |
1-20-2022 Insider Buy |
James Peyer Director and >10% Owner |
$5.10
CAGR »
|
$154,312.68 30,244 shares |
1-18-2022 Insider Buy |
Biopharma Inc Cambrian >10% Owner |
$5.08
CAGR »
|
$50,800.00 10,000 shares |
1-18-2022 Insider Buy |
James Peyer Director and >10% Owner |
$5.08
CAGR »
|
$50,800.00 10,000 shares |
1-14-2022 Insider Buy |
Biopharma Inc Cambrian >10% Owner |
$5.10
CAGR »
|
$133,391.70 26,172 shares |
1-14-2022 Insider Buy |
James Peyer Director and >10% Owner |
$5.10
CAGR »
|
$133,391.70 26,172 shares |
1-12-2022 Insider Buy |
Biopharma Inc Cambrian >10% Owner |
$5.20
CAGR »
|
$104,211.54 20,047 shares |
1-12-2022 Insider Buy |
James Peyer Director and >10% Owner |
$5.20
CAGR »
|
$104,211.54 20,047 shares |
1-10-2022 Insider Buy |
Biopharma Inc Cambrian >10% Owner |
$5.28
CAGR »
|
$52,800.00 10,000 shares |
1-10-2022 Insider Buy |
James Peyer Director and >10% Owner |
$5.28
CAGR »
|
$52,800.00 10,000 shares |
12-30-2021 Insider Buy |
Biopharma Inc Cambrian >10% Owner |
$4.85
CAGR »
|
$5,465.95 1,127 shares |
12-30-2021 Insider Buy |
James Peyer Director and >10% Owner |
$4.85
CAGR »
|
$5,465.95 1,127 shares |
12-29-2021 Insider Buy |
Biopharma Inc Cambrian >10% Owner |
$4.98
CAGR »
|
$343,620.00 69,000 shares |
12-29-2021 Insider Buy |
James Peyer Director and >10% Owner |
$4.98
CAGR »
|
$343,620.00 69,000 shares |
12-28-2021 Insider Buy |
James Peyer Director and >10% Owner |
$5.28
CAGR »
|
$59,600.64 11,288 shares |
12-28-2021 Insider Buy |
Biopharma Inc Cambrian >10% Owner |
$5.28
CAGR »
|
$59,600.64 11,288 shares |
12-27-2021 Insider Buy |
Biopharma Inc Cambrian >10% Owner |
$5.30
CAGR »
|
$19,673.60 3,712 shares |
12-27-2021 Insider Buy |
James Peyer Director and >10% Owner |
$5.30
CAGR »
|
$19,673.60 3,712 shares |
12-23-2021 Insider Buy |
Biopharma Inc Cambrian >10% Owner |
$5.27
CAGR »
|
$57,970.00 11,000 shares |
12-23-2021 Insider Buy |
James Peyer Director and >10% Owner |
$5.27
CAGR »
|
$57,970.00 11,000 shares |
12-16-2021 Insider Buy |
Biopharma Inc Cambrian >10% Owner |
$5.25
CAGR »
|
$57,356.25 10,925 shares |
12-10-2021 Insider Buy |
Thomas G. Ricks Director |
$6.24
CAGR »
|
$249,600.00 40,000 shares |
5-5-2021 Insider Buy |
James Peyer Director and >10% Owner |
$12.00
CAGR »
|
$4,200.00 350 shares |
4-20-2021 Insider Buy |
James Peyer Director and >10% Owner |
$12.77
CAGR »
|
$4,916.45 385 shares |
4-20-2021 Insider Buy |
Biopharma Inc Cambrian >10% Owner |
$12.77
CAGR »
|
$4,916.45 385 shares |
4-19-2021 Insider Buy |
Biopharma Inc Cambrian >10% Owner |
$13.38
CAGR »
|
$26,291.70 1,965 shares |
4-19-2021 Insider Buy |
James Peyer Director and >10% Owner |
$13.38
CAGR »
|
$26,291.70 1,965 shares |
4-13-2021 Insider Buy |
Biopharma Inc Cambrian >10% Owner |
$14.00
CAGR »
|
$28,000.00 2,000 shares |
4-13-2021 Insider Buy |
James Peyer Director and >10% Owner |
$14.00
CAGR »
|
$28,000.00 2,000 shares |
4-7-2021 Insider Buy |
Biopharma Inc Cambrian >10% Owner |
$14.00
CAGR »
|
$28,000.00 2,000 shares |
4-1-2021 Insider Buy |
James Peyer Director and >10% Owner |
$14.00
CAGR »
|
$14,000.00 1,000 shares |
4-1-2021 Insider Buy |
Biopharma Inc Cambrian >10% Owner |
$14.00
CAGR »
|
$14,000.00 1,000 shares |
3-30-2021 Insider Buy |
James Peyer Director and >10% Owner |
$12.00
CAGR »
|
$24,000.00 2,000 shares |
3-30-2021 Insider Buy |
Biopharma Inc Cambrian >10% Owner |
$12.00
CAGR »
|
$24,000.00 2,000 shares |
3-24-2021 Insider Buy |
Biopharma Inc Cambrian >10% Owner |
$14.12
CAGR »
|
$52,950.00 3,750 shares |
3-24-2021 Insider Buy |
James Peyer Director and >10% Owner |
$14.12
CAGR »
|
$52,950.00 3,750 shares |
3-22-2021 Insider Buy |
James Peyer Director and >10% Owner |
$15.02
CAGR »
|
$32,788.66 2,183 shares |
3-22-2021 Insider Buy |
Biopharma Inc Cambrian >10% Owner |
$15.02
CAGR »
|
$32,788.66 2,183 shares |
3-18-2021 Insider Buy |
James Peyer Director and >10% Owner |
$15.25
CAGR »
|
$12,459.25 817 shares |
3-8-2021 Insider Buy |
Biopharma Inc Cambrian >10% Owner |
$15.25
CAGR »
|
$15,249.00 1,000 shares |
3-8-2021 Insider Buy |
James Peyer Director and >10% Owner |
$15.25
CAGR »
|
$15,249.00 1,000 shares |
3-4-2021 Insider Buy |
James Peyer Director and >10% Owner |
$15.16
CAGR »
|
$75,800.00 5,000 shares |
3-4-2021 Insider Buy |
Biopharma Inc Cambrian >10% Owner |
$15.16
CAGR »
|
$75,800.00 5,000 shares |
2-26-2021 Insider Buy |
Biopharma Inc Cambrian >10% Owner |
$16.25
CAGR »
|
$81,250.00 5,000 shares |
2-22-2021 Insider Buy |
James Peyer Director and >10% Owner |
$18.88
CAGR »
|
$185,061.76 9,802 shares |
2-22-2021 Insider Buy |
Biopharma Inc Cambrian >10% Owner |
$18.88
CAGR »
|
$185,061.76 9,802 shares |
2-18-2021 Insider Buy |
James Peyer Director and >10% Owner |
$19.75
CAGR »
|
$14,871.75 753 shares |
2-18-2021 Insider Buy |
Biopharma Inc Cambrian >10% Owner |
$19.75
CAGR »
|
$14,871.75 753 shares |
Also See: Institutional Holders of SNSE
Also See: SEC filings
Below we present the annualized performance delivered by Sensei Biotherapeutics stock since 9-11-2023 (the date of the most recent
insider purchase). The performance of the investment from the time Sensei Biotherapeutics insider buying occurred is the ultimate
test of whether insiders were right about SNSE being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
09/12/2023 |
|
End date: |
04/17/2024 |
|
Start price/share: |
$0.78 |
|
End price/share: |
$1.00 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
28.21% |
|
Annualized Gain: |
47.22% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$12,821.00 |
|
Years: |
0.60 |
|
Sensei Biotherapeutics Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent Sensei Biotherapeutics insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding SNSE
|
|